As co-founder of the Translational Sciences Division, Devangi will be building partnerships directly with clients to provide translational strategies, facilitate regulatory engagements and deliver the assays, datasets and integrated analyses to advance their drug development programs.

Devangi is a recognized thought leader in translational sciences and has led scientific teams responsible for developing and executing stage-appropriate biomarker and bioanalytical strategies that support internal program decision-making, regulatory submissions, post-marketing and drug-positioning goals. She brings more than 14 years of drug development experience, with deep expertise in designing integrated biomarker and bioanalytical strategies as well as developing PK, immunogenicity and biomarker assays to support drug programs from discovery to post-market and spanning multiple disease indications. Externally, Devangi has special interests in advancing industry-wide best practices for assay development and “fit-for-purpose” validation of ligand-binding and flow cytometry biomarker assays. She is an invited speaker at multiple biomarker and bioanalytical conferences, contributor to industry white papers, and has numerous publications of her translational and medical research in peer reviewed journals.